Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $18.00.

Several equities research analysts have recently issued reports on the stock. Piper Sandler upgraded shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price target for the company in a research note on Wednesday, July 8th. Lucid Cap Mkts upgraded Tvardi Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 8th. HC Wainwright assumed coverage on Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 price objective for the company. Wall Street Zen raised Tvardi Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 12th. Finally, BTIG Research lowered their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th.

Tvardi Therapeutics Stock Performance

TVRD opened at $1.62 on Friday. The firm has a market cap of $21.61 million, a P/E ratio of -0.58 and a beta of 0.32. The firm has a 50-day moving average of $2.13 and a 200 day moving average of $2.84. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Equities research analysts predict that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tvardi Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TVRD. BlackRock Inc. bought a new position in Tvardi Therapeutics during the second quarter worth about $181,000. Susquehanna International Group LLP bought a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $63,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $34,000. 44.66% of the stock is currently owned by institutional investors.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s approach is designed to address tumor growth, immune suppression and resistance to existing therapies by selectively targeting STAT3, a protein involved in cancer progression.

Tvardi’s lead product candidate is TTI-101, an orally administered small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors.